Roche Holding Ltd · SIX:RO
Roche — Goldman Sachs 21st Annual Medtech and Healthcare Services Conference (September 2024)
25 slides from Roche's conference presentation, Sep 4, 2024
Slide 1: Slide 1
Slide 2: Goldman Sachs Conference, London, 4 September 2024
Goldman Sachs Conference London, 4 September 2024
Slide 3: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 4: Agenda for today
1. Market trends 2. Roche Diagnostics strategy and Agenda for today goals 3. Roche Diagnostics pipeline highlights
Slide 5: Market trends in healthcare
Market trends in healthcare Novel treatments Decentralization of care: Earlier treatment enabled by earlier diagnosis and diagnostics for diseases testing and collection moving (e.g. cancer detection) without existing interventions closer to patients (e.g., Alzheimer’s disease) Continuing consolidat
Slide 6: Roche Diagnostics strategy
Roche Diagnostics strategy Driving continued and sustainable success Our vision: Innovating diagnostics, shaping healthcare, changing lives Improve care along DISEASE MANAGEMENT patient journeys SOLUTIONS Outcomes Enable confident healthcare HEALTHCARE DECISION Costs decisions SUPPORT SOLUTIONS Deli
Slide 7: Roche Diagnostics product areas focus
Roche Diagnostics product areas focus Customer Areas spanning diverse disciplines and settings in the clinical lab and near patient care Customer area Core Lab Molecular Lab Pathology Lab Near Patient Care Products • Serum Work Area (immuno- • Molecular diagnostics2 • Primary staining (H&E) • Diabet
Slide 8: Our Goals as Roche Diagnostics
Our Goals as Roche Diagnostics Impact for patients, society and our business Maintain and expand Invest to become a Differentiate through Enable disease our #1 position in leader in decentralized comprehensive solutions management for better the clinical testing across highest burden patient outcome
Slide 9: Roche Diagnostics financial ambition
Roche Diagnostics financial ambition Strong sales growth with margin improvement expected, driven by existing business and emerging opportunities Growth and profit drivers ● Continued strong on-market portfolio growth ● Continued business expansion in major and Roche Diagnostics ambition growth mark
Slide 10: Maintain and expand our #1 position in the clinical laboratory
Deliver medical value on integrated testing solutions Maintain and expand our #1 position in the clinical laboratory Invest to become a leader in decentralized testing Enable confident healthcare decisions Deliver medical value on integrated testing solutions
Slide 11: Global commercial footprint
Leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing Global commercial footprint Broad geographic presence will continue to drive commercial expansion globally Roche Diagnostics footprint Key takeaways 20,000+ commercial employees4 serving patients i
Slide 12: System portfolio and pipeline including transformative solutions
Leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing System portfolio and pipeline including transformative solutions Non-exhaustive Continue to deliver Disrupt the market with Invest to become a leader in in areas of strength transformative innovati
Slide 13: cobas 6800/8800 version 2.0
Leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing cobas® 6800/8800 version 2.0 Retrofittable upgrade with increased testing flexibility, higher throughput and greater automation CE launch in Market opportunity Q4 2024 • Strategic unlocking of inst
Slide 14: cobas Mass Spectrometry
Leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing cobas® Mass Spectrometry First fully integrated IVD platform for clinical mass spectrometry CE launch in Market opportunity Q4 2024 • Current total mass spectrometry market to be addressed: CHF 3bn
Slide 15: LumiraDx
Leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing LumiraDx Potentially disruptive solution for the Point of Care setting LumiraDx key attributes Value to healthcare systems and Roche • Multi-modal technology that can perform Consolidate Point of C
Slide 16: Differentiate through comprehensive solutions across highest burden disease areas
Differentiate through comprehensive solutions across highest burden disease areas Enable confident healthcare decisions Deliver medical value on integrated testing solutions
Slide 17: Assay pipeline by customer area
Leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing Assay pipeline by customer area Strong pipeline of assay launches with ~130 new tests in the next three years1 Innovative Smart gap fills Σ Highlights (not exhaustive) Amyloid Plasma Panel2 NfL2 Tn
Slide 18: Elecsys IGRA Tuberculosis (TB)
Leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing Elecsys® IGRA Tuberculosis (TB) Addressing highly attractive TB IGRA segment and strengthening Roche's Infectious Disease offering Functional test for T cell reactivity potential Market opportunity
Slide 19: cobas Respiratory flex for use on cobas x800 Systems
Leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing cobas® Respiratory flex for use on cobas® x800 Systems Flexible syndromic testing empowered by Roche’s novel and proprietary TAGS technology Empowered by TAGS 5 channels = up to 15 targets Market o
Slide 20: Elecsys pTau 217 test
Leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing Elecsys® pTau 217 test 4 recent BDDs in neurology indications strongly position Roche to serve high unmet needs Recent Neurology BDDs1 Elecsys® pTau217 test in Alzheimer’s Disease 2 Elecsys® β-Amyl
Slide 21: Enable disease management for better patient outcomes
Enable disease management for better patient outcomes Improve care along patient journeys Enable confident healthcare decisions Deliver medical value on integrated testing solutions 21
Slide 22: Accu-Chek SmartGuide CGM solution
Leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing Accu-Chek SmartGuide CGM solution CE mark received in July Accu-Chek SmartGuide CGM solution Improving diabetes management and care continuum • 14 days of reliable and accurate real-time glucose se
Slide 23: Digital solutions pipeline
A leader in #1 in the Highest burden Disease decentralized clinical lab disease areas management testing Digital solutions pipeline ~40 on-market solutions; ~15 in the pipeline incl. 30 new algorithms over the next three years1 On market In development Pipeline highlights (non-exhaustive) Clinical n
Slide 24: Roche setting new standards for IVD and Healthcare
Roche setting new standards for IVD and Healthcare We will enhance the We are the IVD We are delivering patient impact of our industry leader with a innovative solutions to products with digital clear strategy to grow the largest healthcare challenges in society and AI powered above the market solut
Slide 25: Doing now what patients need next
Doing now what patients need next
Roche — Goldman Sachs 21st Annual Medtech and Healthcare Services Conference (September 2024) on 6ix